Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage company developing VT-7208, a BTK inhibitor for immune-mediated diseases, will present at two investor conferences.

Rhea-AI Summary

Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage company developing VT-7208, a BTK inhibitor for immune-mediated diseases, will present at two investor conferences. Sheila Gujrathi, M.D., board member and founder and former executive chair of Vidya Therapeutics, will present on September 10 at 10:15 a.m. ET at the Wells Fargo 21st Annual Healthcare Conference and on September 11 at 7:00 a.m. ET at the H.C. Wainwright 28th Annual Global Investment Conference.

In July 2026, Processa announced the stock-for-stock acquisition of Vidya Therapeutics and an oversubscribed private placement of approximately $200 million to advance VT-7208 and fund future operations. A special meeting is planned in Q4 2026 to seek approval for conversion of preferred stock issued in the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences.

Sheila Gujrathi, M.D., a member of the Processa board of directors and founder and former executive chair of Vidya Therapeutics, will give a company presentation at the following:

• Thursday, September 10, at 10:15 a.m. ET at the Wells Fargo 21st Annual Healthcare Conference. Register for the webcast here.

• Friday, September 11, at 7 a.m. ET at the H.C. Wainwright 28th Annual Global Investment Conference. Register for the webcast here.

In July 2026, Processa announced the acquisition of Vidya Therapeutics in a stock-for-stock transaction under a merger agreement, alongside an oversubscribed private placement financing of approximately $200 million to support the advancement of VT-7208 across multiple immune-mediated diseases and establish the foundation for the combined company’s future operations. Processa plans to hold a special meeting in the fourth quarter of this year to seek approval for the conversion of the preferred stock issued in the transaction.

ABOUT PROCESSA PHARMACEUTICALS

Processa Pharmaceuticals is a clinical-stage pharmaceutical company advancing innovative drug candidates through a disciplined, science-driven development strategy. Following the acquisition of Vidya Therapeutics, Processa’s lead program is VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. VT-7208 is a potentially best-in-class BTK inhibitor (BTKi) designed to improve on the efficacy and safety of early-generation programs. Processa is developing VT-7208 in three parallel programs: food allergy and chronic spontaneous urticaria (CSU) in immunology, and relapsing multiple sclerosis (RMS) in neurology, where its CNS-penetrant profile addresses an area of high unmet need. With Phase 1 complete, the company intends to advance all three programs toward Phase 2 proof-of-concept studies, with initial data expected in 2027 and 2028.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Processa, Vidya, the concurrent private placement financing and the acquisition of Vidya by Processa (the “Transactions”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Transactions and the expected effects, perceived benefits or opportunities and related timing with respect to the Transactions; expectations regarding or plans for VT-7208, including its planned clinical trials, research and development programs and the expected timing for key milestones, including the release of clinical data; the potential benefits of VT-7208; and expectations regarding the use of proceeds from the concurrent private placement financing and cash runway expectations therefrom, including such proceeds funding the company through key clinical milestones. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company or the Transactions will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading “Risk Factors” and in the company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2026 and Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2026, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Vidya, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.

CONTACTS
Investors
Priyanka Shah
Elephant Head Communications
pshah@elephantheadcommunicationsllc.com

Media
Ryan Flinn
The Grace Group
ryan@gracegroup.us

FAQ

What upcoming investor conferences will Processa Pharmaceuticals (NASDAQ: PCSA) participate in September 2026?

Processa will present at the Wells Fargo 21st Annual Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. According to Processa, presentations are scheduled for September 10, 2026 at 10:15 a.m. ET and September 11, 2026 at 7:00 a.m. ET.

Who will present for Processa Pharmaceuticals (PCSA) at the Wells Fargo Healthcare Conference on September 10, 2026?

Sheila Gujrathi, M.D., a Processa board member, will present at the Wells Fargo conference. According to Processa, she is also the founder and former executive chair of Vidya Therapeutics, providing investor updates on the company and its BTK inhibitor VT-7208 program.

What were the key terms of Processa Pharmaceuticals’ July 2026 acquisition of Vidya Therapeutics (PCSA)?

Processa announced a stock-for-stock acquisition of Vidya Therapeutics under a merger agreement in July 2026. According to Processa, the deal was paired with an oversubscribed private placement of approximately $200 million to support VT-7208 development and future operations of the combined company.

How much capital did Processa Pharmaceuticals (NASDAQ: PCSA) raise in its July 2026 private placement financing?

Processa reported an oversubscribed private placement financing of approximately $200 million in July 2026. According to Processa, the proceeds are intended to advance VT-7208 across multiple immune-mediated diseases and help establish the operational foundation of the combined company after acquiring Vidya Therapeutics.

What is VT-7208 in Processa Pharmaceuticals’ (PCSA) pipeline and what diseases is it targeting?

VT-7208 is a Bruton's tyrosine kinase (BTK) inhibitor being developed by Processa for immune-mediated diseases. According to Processa, funding from the Vidya Therapeutics acquisition and $200 million private placement will support advancing VT-7208 across multiple immune-mediated indications.

When will Processa Pharmaceuticals hold its special meeting related to preferred stock from the Vidya merger (PCSA)?

Processa plans to hold a special shareholder meeting in the fourth quarter of 2026. According to Processa, the meeting will seek approval for the conversion of preferred stock issued in connection with the stock-for-stock acquisition of Vidya Therapeutics.